From GlobeNewswire: 2025-05-05 06:00:00

Recursion, a clinical stage TechBio company, has advanced its pipeline strategy by focusing on 5+ clinical and preclinical programs in oncology and rare diseases. They achieved a milestone with Sanofi, generating $7 million for a lead in autoimmune diseases. The company has streamlined operations to maintain cash runway until mid-2027.

In a recent business update, Recursion highlighted advances in its pipeline, including preliminary data on REC-4881 in familial adenomatous polyposis. They also provided updates on REC-7735 for breast cancer and REV102 for hypophosphatasia. The company is focused on core therapeutic areas like oncology and rare diseases, with additional discovery programs in progress.

Recursion announced a milestone in its partnership with Sanofi, receiving a $7 million payment for a small-molecule lead targeting an immune cell. This partnership has generated $130 million in cash inflows for Recursion to date. The company also continues to collaborate with Roche and Genentech on programs in GI Oncology and Neuroscience.

The platform updates at Recursion include leveraging data assets from Tempus and HealthVerity to enhance clinical development. They have partnered with Enamine to create screening libraries targeting key drug targets. The company is utilizing AI and automation to improve drug discovery efficiency.

Financially, Recursion reported a cash position of $509 million as of March 31, 2025. They had total revenue of $15 million for the first quarter, with research and development expenses at $130 million. The company’s net loss for the quarter was $203 million, with a cash burn of $118 million. Recursion expects a cash runway into mid-2027 based on their current business plan.

Recursion has appointed Namandjé Bumpus, Ph.D, and Elaine Sun to its Board of Directors. The company is committed to advancing drug discovery through technology, biology, and chemistry to improve patient outcomes. Their innovative approach aims to revolutionize the future of medicine.



Read more at GlobeNewswire:: Recursion Reports First Quarter 2025 Financial Results and